Cohance Lifesciences receives warning letter for its Nacharam formulation facility

Last Updated : Feb 04 2026 | 12:32 PM IST

From the USFDA

Pursuant to the USFDA inspection, Cohance Lifesciences has received a warning letter for the company's Nacharam formulation facility.

The Company had earlier informed the Stock Exchanges that the facility was classified as Official Action Indicated (OAI), and the said Warning Letter is in continuation of the same.

The inspection was conducted by the USFDA from 04 August 2025 to 12 August 2025.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Connect with us on WhatsApp

Barometers trade with significant gains; auto shares rally for 2nd day

Rubicon Research surges after Q3 PAT jumps 91% YoY to Rs 73 cr

Kansai Nerolac slides as Q3 PAT slumps 75% YoY to Rs 131 cr

ADF Foods spurts after Q3 PAT rises nearly 56% YoY

Gokaldas Exports Ltd leads gainers in 'A' group

First Published: Feb 04 2026 | 12:32 PM IST